» Articles » PMID: 27469363

Molecular Imaging of Immunotherapy Targets in Cancer

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2016 Jul 30
PMID 27469363
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Immunotherapy has emerged as a promising alternative in the arsenal against cancer by harnessing the power of the immune system to specifically target malignant tissues. As the field of immunotherapy continues to expand, researchers will require newer methods for studying the interactions between the immune system, tumor cells, and immunotherapy agents. Recently, several noninvasive imaging strategies have been used to map the biodistribution of immune checkpoint molecules, monitor the efficacy and potential toxicities of the treatments, and identify patients who are likely to benefit from immunotherapies. In this review, we outline the current applications of noninvasive techniques for the preclinical imaging of immunotherapy targets and suggest future pathways for molecular imaging to contribute to this developing field.

Citing Articles

Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.

Malicki S, Czarna A, Zyla E, Pucelik B, Galan W, Chruscicka B Sci Rep. 2024; 14(1):28652.

PMID: 39562585 PMC: 11576874. DOI: 10.1038/s41598-024-74891-7.


Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications.

Malik M, Alqahtani M, Hadadi I, Kanbayti I, Alawaji Z, Aloufi B Diagnostics (Basel). 2024; 14(21).

PMID: 39518426 PMC: 11545511. DOI: 10.3390/diagnostics14212459.


A PD-L1-Targeted Probe Cy5.5-A11 for Imaging of Multiple Tumors.

Cao X, Mao X, Lu S, Zhu W, Huang W, Yi H ACS Omega. 2024; 9(43):43826-43833.

PMID: 39494025 PMC: 11525735. DOI: 10.1021/acsomega.4c06761.


PET imaging of colon cancer CD73 expression using cysteine site-specific Zr-labeled anti-CD73 antibody.

Jung K, Kim M, Jung H, Koo H, Kim J, Lee H Sci Rep. 2024; 14(1):17994.

PMID: 39097625 PMC: 11297922. DOI: 10.1038/s41598-024-68987-3.


Peptide-based PET imaging agent of tumor TIGIT expression.

Weng D, Guo R, Zhu Z, Gao Y, An R, Zhou X EJNMMI Res. 2023; 13(1):38.

PMID: 37129788 PMC: 10154443. DOI: 10.1186/s13550-023-00982-7.


References
1.
Kim D, Trinh V, Hwu W . Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014; 14(11):1709-18. DOI: 10.1517/14712598.2014.963053. View

2.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

3.
Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M . 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014; 9(11):e109866. PMC: 4217715. DOI: 10.1371/journal.pone.0109866. View

4.
Antczak A, Pastuszak-Lewandoska D, Gorski P, Domanska D, Migdalska-Sek M, Czarnecka K . Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int. 2013; 2013:576486. PMC: 3722891. DOI: 10.1155/2013/576486. View

5.
Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View